Copyright 2009 Medical News Today Latest ADHD News From Medical News Today. http://www.medicalnewstoday.com/sections/adhd/ admin@medicalnewstoday.com (MNT Admin) editors@medicalnewstoday.com (MNT Editors) en-us Thu, 02 Jul 2009 01:00:00 PDT http://www.medicalnewstoday.com/articles/156067.php http://www.medicalnewstoday.com/articles/156067.php Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced results from a Phase 3b study that found VYVANSE® (lisdexamfetamine dimesylate) CII demonstrated significant efficacy at 14 hours after administration during a simulated workplace environment study in adults with Attention Deficit Hyperactivity Disorder (ADHD). ADHD Thu, 25 Jun 2009 01:00:00 PDT http://www.medicalnewstoday.com/articles/155233.php http://www.medicalnewstoday.com/articles/155233.php People with a learning disability will be helped into paid jobs to close the employment gap, Jonathan Shaw, Minister for Disabled People and Phil Hope, Minister for Care Services pledged today. The goal is set out in the new cross-government Learning Disability Employment Strategy, published today. The strategy sets out a vision to increase the number of real jobs for people with learning disabilities with appropriate support being provided. Mental Health Wed, 24 Jun 2009 03:00:00 PDT http://www.medicalnewstoday.com/articles/155087.php http://www.medicalnewstoday.com/articles/155087.php Pediatric researchers have identified hundreds of gene variations that occur more frequently in children with attention-deficit hyperactivity disorder (ADHD) than in children without ADHD. Many of those genes were already known to be important for learning, behavior, brain function and neurodevelopment, but had not been previously associated with ADHD. ADHD Thu, 18 Jun 2009 01:00:00 PDT http://www.medicalnewstoday.com/articles/154341.php http://www.medicalnewstoday.com/articles/154341.php This week, a study came out that scared us big-time ... it suggests that children and teens who take stimulants like Ritalin for ADHD have an increased risk for sudden cardiac death. Our pediatrician weighs in. A new study in The American Journal of Psychiatry suggests that children and teens who take stimulants like Ritalin for ADHD have an increased risk for sudden cardiac death. ADHD Tue, 16 Jun 2009 02:00:00 PDT http://www.medicalnewstoday.com/articles/154030.php http://www.medicalnewstoday.com/articles/154030.php A new study by researchers in the US suggests there may be a link between the use of stimulant drugs for attention-deficit hyperactivity disorder (ADHD) and sudden cardiac death in healthy children, but the US Food and Drug Administration (FDA), who funded the study with the National In ADHD Tue, 16 Jun 2009 01:00:00 PDT http://www.medicalnewstoday.com/articles/153989.php http://www.medicalnewstoday.com/articles/153989.php There may be an association between the use of stimulant medications for attention-deficit hyperactivity disorder, known as ADHD, and sudden cardiac death in healthy children, according to a study published in the American Journal of Psychiatry. But the U.S. Food and Drug Administration says that, because of the study's limitations, parents should not stop a child's stimulant medication based on the study. ADHD Thu, 11 Jun 2009 00:00:00 PDT http://www.medicalnewstoday.com/articles/153347.php http://www.medicalnewstoday.com/articles/153347.php Residential childcare and fostering agency, Perpetual Care, and the University of Central Lancashire's School of Nursing & Caring Sciences are jointly developing an introductory workshop on the ground-breaking Nurtured Heart Approach, which seeks to improve social and educational outcomes for many children and young people. ADHD Sun, 07 Jun 2009 01:00:00 PDT http://www.medicalnewstoday.com/articles/152827.php http://www.medicalnewstoday.com/articles/152827.php InfoMedics, Inc., the patient feedback company, recently co-authored two posters detailing patients' experiences with the attention-deficit/hyperactivity disorder (ADHD) drug lisdexamfetamine dimesylate (LDX). The posters were presented at the American Psychiatric Association (APA) and the College of Psychiatric and Neurologic Pharmacists' (CPNP) annual meetings. ADHD Thu, 04 Jun 2009 00:00:00 PDT http://www.medicalnewstoday.com/articles/152459.php http://www.medicalnewstoday.com/articles/152459.php Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has approved a change to the prescribing information for its once-daily Attention Deficit Hyperactivity Disorder (ADHD) treatment VYVANSE® (lisdexamfetamine dimesylate) CII, to include supplemental data that demonstrated significant ADHD symptom control in children aged 6 to 12 from the first time point measured (1. ADHD Wed, 03 Jun 2009 00:00:00 PDT http://www.medicalnewstoday.com/articles/152282.php http://www.medicalnewstoday.com/articles/152282.php Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that the US Food and Drug Administration (FDA) has approved a change to the prescribing information for its once-daily Attention Deficit Hyperactivity Disorder (ADHD) treatment VYVANSE® (lisdexamfetamine dimesylate) CII, to include supplemental data that demonstrated significant ADHD symptom control in children aged 6 to 12 from the first time point measured (1. ADHD Thu, 28 May 2009 06:00:00 PDT http://www.medicalnewstoday.com/articles/151729.php http://www.medicalnewstoday.com/articles/151729.php A Canadian researcher working in the U.K. says doctors, authors and educators are doing hyperactive children a disservice by claiming that hyperactivity as we understand it today has always existed. Matthew Smith says not only is that notion wrong, it misleads patients, their parents and their physicians. Smith, who is from Edmonton, is finishing up his PhD at the Centre for Medical History at the University of Exeter. ADHD Thu, 28 May 2009 03:00:00 PDT http://www.medicalnewstoday.com/articles/151665.php http://www.medicalnewstoday.com/articles/151665.php Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced results of a study showing that coadministration of the ADHD medication VYVANSE® (lisdexamfetamine dimesylate) CII with the proton pump inhibitor (PPI) Prilosec OTC® 40 mg (20 mg X 2), did not alter the median time it took for maximum plasma concentration of d-amphetamine to be reached in the subjects evaluated. ADHD Wed, 27 May 2009 04:00:00 PDT http://www.medicalnewstoday.com/articles/151505.php http://www.medicalnewstoday.com/articles/151505.php Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced results of a European survey that found a child's Attention Deficit Hyperactivity Disorder (ADHD) symptoms at school were a key concern for parents, yet outside of school their child's ADHD also had significant impact on parents' personal time.1 The survey also revealed key findings surrounding parents' role in assessment and treatment for their child. ADHD Tue, 26 May 2009 04:00:00 PDT http://www.medicalnewstoday.com/articles/151377.php http://www.medicalnewstoday.com/articles/151377.php As thousands of students nationwide prepare to leave high school, a UC Davis study appearing online in the June issue of the medical journal Pediatrics shows a clear link between attention problems early in school - as early as kindergarten - and lower high school test scores. Pediatrics / Children's Health Mon, 25 May 2009 00:00:00 PDT http://www.medicalnewstoday.com/articles/151211.php http://www.medicalnewstoday.com/articles/151211.php Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced results of a study showing that coadministration of the ADHD medication VYVANSE® (lisdexamfetamine dimesylate) CII with the proton pump inhibitor (PPI) Prilosec OTC® 40 mg (20 mg X 2), did not alter the median time it took for maximum plasma concentration of d-amphetamine to be reached in the subjects evaluated. ADHD Thu, 21 May 2009 05:00:00 PDT http://www.medicalnewstoday.com/articles/150954.php http://www.medicalnewstoday.com/articles/150954.php Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced new findings on INTUNIV (guanfacine) extended release, a selective alpha-2A-agonist, at a major psychiatric meeting. This randomized placebo controlled trial met its primary objective, which was to evaluate the effects of INTUNIV on oppositional symptoms in children aged 6 to 12 years with a diagnosis of ADHD and the presence of oppositional symptoms. ADHD Tue, 19 May 2009 07:00:00 PDT http://www.medicalnewstoday.com/articles/150640.php http://www.medicalnewstoday.com/articles/150640.php Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments lisdexamfetamine dimesylate (CII) and investigational non-scheduled guanfacine extended release, at a national scientific meeting of psychiatrists being held May 16 -21 in San Francisco, CA. ADHD Tue, 19 May 2009 01:00:00 PDT http://www.medicalnewstoday.com/articles/150478.php http://www.medicalnewstoday.com/articles/150478.php Superior intelligence is no defense against the effects of attention deficit and hyperactivity disorder, Yale researchers have found. About three of four ADHD individuals with an IQ of more than 120 - a score that ranks them in the top nine percent of the U.S. population - showed significant impairments in memory and cognitive tests when compared to people with similar IQ's who do not suffer from the disorder, according to the researchers. ADHD Tue, 05 May 2009 06:00:00 PDT http://www.medicalnewstoday.com/articles/148867.php http://www.medicalnewstoday.com/articles/148867.php Children who have high blood pressure are more likely to have learning disabilities and attention deficit hyperactivity disorder (ADHD) than children who are not hypertensive. They are also more likely to have a higher body mass index (BMI), an indicator of body fat. Pediatrics / Children's Health Mon, 04 May 2009 02:00:00 PDT http://www.medicalnewstoday.com/articles/148636.php http://www.medicalnewstoday.com/articles/148636.php A study in the May 1 issue of the journal SLEEP shows that adolescents with a childhood diagnosis of Attention Deficit/Hyperactivity Disorder (ADHD) are more likely to have current and lifetime sleep problems and disorders, regardless of the severity of current ADHD symptoms. Authors suggest that findings indicate that mental health professionals should screen for sleep problems and psychiatric comorbidities among all adolescents with a childhood diagnosis of ADHD. ADHD Wed, 29 Apr 2009 02:00:00 PDT http://www.medicalnewstoday.com/articles/147996.php http://www.medicalnewstoday.com/articles/147996.php A new Cochrane review finds no evidence to support the use of risperidone to treat attention- deficit/hyperactivity disorder (ADHD) in people with intellectual disabilities, even though the review authors say this is a common prescribing pattern. Risperidone, or Risperdal, is a second-generation antipsychotic drug. Long-term use of these drugs is associated with serious side effects, including weight gain and increased risk for type 2 diabetes. ADHD Tue, 28 Apr 2009 06:00:00 PDT http://www.medicalnewstoday.com/articles/147894.php http://www.medicalnewstoday.com/articles/147894.php A recent Finnish study suggests that children's short sleep duration even without sleeping difficulties increases the risk for behavioral symptoms of ADHD. During the recent decades, sleep duration has decreased in many countries; in the United States a third of children are estimated to suffer from inadequate sleep. Sleep / Sleep Disorders / Insomnia Sun, 26 Apr 2009 01:00:00 PDT http://www.medicalnewstoday.com/articles/147522.php http://www.medicalnewstoday.com/articles/147522.php Sciele Pharma, a Shionogi Company, and Addrenex Pharmaceuticals, Inc. announced that a preliminary analysis showed positive results from a second Phase III trial of Clonicel®, demonstrating that the combination of Clonicel with stimulants provided statistically significant improvements in ADHD symptoms compared to stimulant used alone. Larry Dillaha, M.D. ADHD Fri, 24 Apr 2009 07:00:00 PDT http://www.medicalnewstoday.com/articles/147421.php http://www.medicalnewstoday.com/articles/147421.php Addrenex Pharmaceuticals Inc. announced positive results from a second phase 3 trial of Clonicel demonstrating that the combination of Clonicel with stimulant medications provided statistically significant improvements in attention deficit hyperactivity disorder symptoms compared to stimulant use alone. ADHD Fri, 24 Apr 2009 04:00:00 PDT http://www.medicalnewstoday.com/articles/147344.php http://www.medicalnewstoday.com/articles/147344.php Addrenex Pharmaceuticals, Inc. announced positive results from a second phase 3 trial of Clonicel demonstrating that the combination of Clonicel with stimulant medications provided statistically significant improvements in attention deficit hyperactivity disorder (ADHD) symptoms compared to stimulant use alone. ADHD